Lung Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Non Small Cell Lung Cancer (3075)

Lung Non-Squamous Non-Small Cell Cancer (123)

Lung Non-Small Cell Squamous Cancer (97)

Non Small Cell Lung Cancer (3075)

Lung Non-Squamous Non-Small Cell Cancer (123)

Lung Non-Small Cell Squamous Cancer (97)

›

MET F1200I	Lung Adenocarcinoma	MET F1200I	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y	Lung Adenocarcinoma	MET H1094Y	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days (New C4) TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5d	TPX-0022 Sensitive: C4 – Case Studies IASLC-TTLC 2023 - 5 days TPX-0022 Sensitive : C4 IASLC-TTLC 2023 - 5 days - (New C4)
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week (New C4) alectinib Sensitive : C4 Anticancer Drugs - 1wk	alectinib Sensitive: C4 – Case Studies Anticancer Drugs - 1 week alectinib Sensitive : C4 Anticancer Drugs - 1 week - (New C4)
EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR C797S	Lung Adenocarcinoma	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks (New C4) osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2wk	osimertinib + anlotinib Sensitive: C4 – Case Studies Pharmacol Res - 2 weeks osimertinib + anlotinib Sensitive : C4 Pharmacol Res - 2 weeks - (New C4)
EGFR L860R	Lung Adenocarcinoma	EGFR L860R	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks (New D) osimertinib Sensitive : D Cancer Lett - 2wk	osimertinib Sensitive: D – Preclinical Cancer Lett - 2 weeks osimertinib Sensitive : D Cancer Lett - 2 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	vinorelbine tartrate Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) vinorelbine tartrate Sensitive : D J Thorac Dis - 4wk	vinorelbine tartrate Sensitive: D – Preclinical J Thorac Dis - 4 weeks vinorelbine tartrate Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	midostaurin Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) midostaurin Sensitive : D J Thorac Dis - 4wk	midostaurin Sensitive: D – Preclinical J Thorac Dis - 4 weeks midostaurin Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	doxorubicin hydrochloride Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) doxorubicin hydrochloride Sensitive : D J Thorac Dis - 4wk	doxorubicin hydrochloride Sensitive: D – Preclinical J Thorac Dis - 4 weeks doxorubicin hydrochloride Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	sunitinib Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) sunitinib Sensitive : D J Thorac Dis - 4wk	sunitinib Sensitive: D – Preclinical J Thorac Dis - 4 weeks sunitinib Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	paclitaxel Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) paclitaxel Sensitive : D J Thorac Dis - 4wk	paclitaxel Sensitive: D – Preclinical J Thorac Dis - 4 weeks paclitaxel Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	lapatinib Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) lapatinib Sensitive : D J Thorac Dis - 4wk	lapatinib Sensitive: D – Preclinical J Thorac Dis - 4 weeks lapatinib Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	etoposide oral Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) etoposide oral Sensitive : D J Thorac Dis - 4wk	etoposide oral Sensitive: D – Preclinical J Thorac Dis - 4 weeks etoposide oral Sensitive : D J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression	Lung Adenocarcinoma	SERPINH1 overexpression	Lung Adenocarcinoma	cyclopamine Sensitive: D – Preclinical J Thorac Dis - 4 weeks (New D) cyclopamine Sensitive : D J Thorac Dis - 4wk	cyclopamine Sensitive: D – Preclinical J Thorac Dis - 4 weeks cyclopamine Sensitive : D J Thorac Dis - 4 weeks - (New D)
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
PD-L1 underexpression	Lung Adenocarcinoma	PD-L1 underexpression	Lung Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	DP Sensitive: A2 - Guideline DP Sensitive : A2	DP Sensitive: A2 - Guideline DP Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	GC Sensitive: A2 - Guideline GC Sensitive : A2	GC Sensitive: A2 - Guideline GC Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2	durvalumab + tremelimumab Sensitive: A2 - Guideline durvalumab + tremelimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cemiplimab Sensitive: A2 - Guideline cemiplimab Sensitive : A2	cemiplimab Sensitive: A2 - Guideline cemiplimab Sensitive : A2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	bevacizumab + erlotinib Sensitive: C1 - Off-label bevacizumab + erlotinib Sensitive : C1	bevacizumab + erlotinib Sensitive: C1 - Off-label bevacizumab + erlotinib Sensitive : C1
PD-L1 expression	Lung Adenocarcinoma	PD-L1 expression	Lung Adenocarcinoma	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
BRAF V600E	Lung Adenocarcinoma	BRAF V600E	Lung Adenocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
ATM mutation	Lung Adenocarcinoma	ATM mutation	Lung Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
RET fusion	Lung Adenocarcinoma	RET fusion	Lung Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1

Lung Adenocarcinoma

Associations(558)

Associations
(558)